Abstract
Background: The graft versus malignancy (GVM) effect after allogeneic hematopoietic stem cell transplantation (alloHSCT) is the most potent form of cancer immunotherapy. However, disease recurrence remains a major contributor to poor outcome and non-specific strategies to enhance GVM responses are frequently complicated by GVHD. Dendritic cell (DC) vaccines may be a strategy to increase the potency and specificity GVM responses but the impact of alloreactivity on DC vaccine responses has not been established.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
